WP-12: Cerebral Morbidity After Radiation Therapy for Brain Tumors

Sponsor
University of Aarhus (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04292353
Collaborator
(none)
67
4
99
16.8
0.2

Study Details

Study Description

Brief Summary

This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.

Condition or Disease Intervention/Treatment Phase
  • Other: Cognitive tests and Patient Reported Outcome

Detailed Description

RT to brain tumours causes cognitive dysfunction. The extent of RT induced changes in cognitive function and radio-sensitivity of the brain is unknown. RT with protons instead of photons spares the healthy brain tissue more and is believed to reduce the risk of cognitive dysfunction. There is modest knowledge on which parts of the brain we need to spare, to prevent cognitive dysfunction.

The study is a prospective nationwide study including approximately 60 brain tumour patients from the four neuro oncology centres in Denmark. The patients will do patient reported outcome (PRO) and undergo neuropsychological assessment with standardized tests: They will do this prior to RT treatment and ½, 1, 3 and 5 years afterwards. The PRO's included measures on quality of life, fatigue, sleep, depression, anxiety, and socio demografica. The standardized tests are: Trail making Test (TMT); Hopkins Verbal Learning Test (HVLT); Controlled Oral Word Association Test (COWAT) - Animals and S; Coding and Digit Span from WAIS-IV; Paced Auditory Serial Addition Test (PASAT). The correlation between cognitive scores and RT dose-volume parameters to specific areas in the brain will be tested.

This study will elucidate the dose-response relationship in radiation-induced damage to substructures of the brain such as hippocampus, thalamus, temporal and frontal lobes that will allow the clinician to prioritize these structures in planning of proton radiotherapy.

Study Design

Study Type:
Observational
Actual Enrollment :
67 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Cerebral Morbidity After Radiation Therapy for Brain Tumors
Actual Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Outcome Measures

Primary Outcome Measures

  1. Impairment of memory as assessed by the HVLT-r test [5 Years]

    Examined by the Hopkins Verbal Learning Test. It will be correlated to the mean radiation dose to the hippocampus. Outcome is number of correct words (0-24)

Secondary Outcome Measures

  1. Processing speed [5 Years]

    Examined by the Trail making Test part A (TMT_A) and the Coding from WAIS-IV. Outcome for TMT_A is time in seconds (0-120 seconds). Outcome for Coding is number of correct (within 2 minutes) (0-100)

  2. Attention and working memory [5 Years]

    Examined by WAIS_IV_digit_span and PASAT (Pased Auditory Seriel Addition Test). Outcome on WAIS digit span is number of correct (0-36) and outcome for PASAT is number of incorrects (0-60)

  3. Verbal learning and memory [5 Years]

    Examine by the Hopkins Verbal Learning Test (HVLT) - total and delayed. Outcome is number of correct words (0-24)

  4. Verbal fluency [5 Years]

    Examined by the Controlled Oral Word Association Test (COWAT) - Animals and letter_S. Outcome is number of words produced in 1 minute (0-100)

  5. Executive function [5 Years]

    Examined by Trail making Test part B (TMT-B) and the STROOP colour and word test (STROOP). Outcome for TMT_B is time in seconds (0-300). Outcome for STROOP is number of corrects (0-120)

  6. Global Health - Quality of life [5 Years]

    Assessed by questionnaire; EORTC QlQ-C30 in order to examine the level of quality of life in brain tumour patients who has received radiation therapy. Quality of life will be assessed by EORTC QIQ-C-30

  7. Fatigue [5 years]

    Assessed by questionnaire: FACIT-Fatigue scale (version 4) in order to explore the level of fatigue in brain tumour patients who has received radiation therapy.

  8. Qulity of Sleep [5 years]

    Assessed by questionnaire:Pittsburg Sleep Quality INDEX, PSQI in order to explore the level of quality of sleep in brain tumour patients who has received radiation therapy

  9. Depression/Anxiety [5 years]

    Assessed by questionnaire: Hospital anxiety and depression Scale (HADS) in order to explore level of depression and anxiety in patients treated with radiation therapy for their brain tumour

  10. Patient's Assessment of Own Functioning Inventory [5 years]

    Assessed by questionnaire; Patient's Assessment of Own Functioning Inventory (PAOFI), in order to assess patients own perception of cognitive function

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years or older and Danish speaking.

  • Performance status WHO 0-2

  • Capable of cooperating on testing

  • Tumor histology (WHO 2016 classification) of the following types: anaplastic astrocytoma (IDH mutant), diffuse astrocytoma (IDH-mutant), gemistocytic astrocytoma (IDH mutant), diffuse astrocytoma (NOS), oligidendroglioma, meningioma, medulloblastoma (NOS), pituitary adenoma, other brain tumours including skull base sarcomas

Exclusion Criteria:
  • Glioblastoma

  • Performance status 3-4

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rigshospital Copenhagen Region H Denmark 2100
2 Department of Oncology Aarhus Region Midt Denmark 8000
3 Aalborg University Hospital Aalborg Region Nord Denmark 9000
4 Odense University Hospital Odense Region Syd Denmark 5000

Sponsors and Collaborators

  • University of Aarhus

Investigators

  • Principal Investigator: Morten Høyer, M.D, Danish Center for Particel Therapy, Aarhus University Hospital, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Morten Høyer, Professor, University of Aarhus
ClinicalTrials.gov Identifier:
NCT04292353
Other Study ID Numbers:
  • WP-12
First Posted:
Mar 3, 2020
Last Update Posted:
May 5, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Morten Høyer, Professor, University of Aarhus
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 5, 2021